Table 2.
Clinical and Histopathological Characteristics Stratified by AR Expression (n = 166)
| Features | AR Positive n = 104 (62.7) | AR Negative n = 62 (37.3) | P-value |
|---|---|---|---|
| Age at Diagnosis | |||
| <40 | 13 (12.5) | 7 (11.3) | 0.193 |
| 40–49 | 23 (22.1) | 22 (35.5) | |
| 50–59 | 23 (22.1) | 15 (24.2) | |
| 60–64 | 15 (14.4) | 9 (14.5) | |
| ≥ 65 | 30 (28.8) | 9 (14.5) | |
| Tumor Size | |||
| T1 | 16 (15.4) | 4 (6.5) | 0.082 |
| T2 | 49 (47.1) | 37 (59.7) | |
| T3 | 21 (20.1) | 16 (25.8) | |
| T4 | 18 (17.3) | 5 (8) | |
| Axillary Nodal Status | |||
| N0 | 54 (51.9) | 35 (56.5) | 0.844 |
| N1 | 28 (26.9) | 15 (24.2) | |
| N2 | 10 (9.6) | 7 (11.3) | |
| N3 | 12 (11.5) | 5 (8) | |
| Grade of Tumor | |||
| I | 13 (12.5) | 2 (3.2) | <0.001* |
| II | 71 (68.3) | 26 (41.9) | |
| III | 20 (19.2) | 34 (54.8) | |
| Stage of Disease | |||
| I | 20 (19.2) | 7 (11.3) | 0.324 |
| II | 55 (52.9) | 39 (62.9) | |
| III | 29 (27.9) | 16 (25.8) | |
| ER Expression | |||
| Positive | 76 (73.1) | 24 (38.7) | <0.001* |
| Negative | 28 (26.9) | 38 (61.3) | |
| PR Expression | |||
| Positive | 66 (63.5) | 21 (33.9) | <0.001* |
| Negative | 38 (36.5) | 41 (66.1) | |
| HER-2/neu Status | |||
| Positive | 32 (30.8) | 18 (29) | 0.813 |
| Negative | 72 (69.2) | 44 (70.9) | |
| CD44 Expression | |||
| Positive | 60 (57.7) | 42 (67.8) | 0.198 |
| Negative | 44 (42.3) | 20 (32.2) | |
| CD24 Expression | |||
| Positive | 56 (53.8) | 17 (27.4) | 0.001* |
| Negative | 48 (46.2) | 45 (72.6) | |
| ALDH1 Expression | |||
| Positive | 24 (23) | 26 (41.9) | 0.010* |
| Negative | 80 (76.9) | 36 (58) | |
| Triple Negative | |||
| Yes | 13 (12.5) | 20 (32.3) | 0.002* |
| No | 91 (87.5) | 42 (67.7) | |